retatrutide phase 2 type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Eli Lilly just announced striking
Pay in 4 interest-free payments of $6.78 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental triple agonist that acts on three gut hormone targets at once. On the top dose, people lost an average of 28% ESC 2024: Retatrutide improves lipid and cardiovascular risk profile in Phase II trial Clinical Trials Arena Phase 2 trial results demonstrate benefits of retatrutide in obesity, type 2 diabetes, NASH ADA Meeting News Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Advancements in Clinical Research and Development of Obesity Treatment Medications
Store: www.allread.ai · Domain: www.allread.ai





























